TrialInvestigational new drugs2020

Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer.

Weiwei Tan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.